Doravirine
- Generic Name
- Doravirine
- Brand Names
- Delstrigo, Pifeltro
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11ClF3N5O3
- CAS Number
- 1338225-97-0
- Unique Ingredient Identifier
- 913P6LK81M
- Background
Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines. Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg).
...
- Indication
Doravirine is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history. It is also indicated to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen ...
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1), Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
"Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk"
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-10-07
- Target Recruit Count
- 226
- Registration Number
- NCT05761509
- Locations
- 🇫🇷
Service de maladies infectieuses et tropicales de de l'hôpital La Pitié-Salpêtrière, Paris, France
🇫🇷Service de maladies infectieuses et tropicales du CHU de Montpellier, Montpellier, France
🇫🇷Hopital Saint Antoine, Paris, France
Doravirine Dose Optimisation in Pregnancy
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- University of Liverpool
- Target Recruit Count
- 76
- Registration Number
- NCT05630638
- Locations
- 🇿🇦
Desmond Tutu Health Foundation, Cape Town, South Africa
HIV A6 Genome In ART Unsuccessful Patients On DOR
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 60
- Registration Number
- NCT05322083
Non-Interventional Observational Retrospective Study to Evaluate Doravirine Based-regimens in HIV Infected Aged Patients (DORAge).
- Conditions
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 90
- Registration Number
- NCT05202613
- Locations
- 🇮🇹
Department of Public Health and Infectious Diseases, Rome, Italy/RM, Italy
Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 10
- Registration Number
- NCT04900974
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Chelsea and Westminster NHS Foundation Trust
- Target Recruit Count
- 150
- Registration Number
- NCT04892654
- Locations
- 🇬🇧
Mortimer Market Centre, London, United Kingdom
🇬🇧Imperial College Healthcare NHS Trust, London, United Kingdom
🇬🇧Chelsea & Westminster Hospital NHS Foundation Trust, London, United Kingdom
Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)
- Conditions
- Interventions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- Target Recruit Count
- 8
- Registration Number
- NCT04689737
- Locations
- 🇪🇸
Universitario Bellvitge Hospital, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
🇪🇸Valle Hebron Hospital, Barcelona, Spain
Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 18
- Registration Number
- NCT04495348
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸UTHealth, Houston, Texas, United States
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)
- Conditions
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 84
- Registration Number
- NCT04375800
- Locations
- 🇨🇴
Clinica Somer ( Site 1003), Rionegro, Antioquia, Colombia
🇺🇸University of Colorado at Denver ( Site 0108), Aurora, Colorado, United States
🇺🇸Emory Children's Center ( Site 0103), Atlanta, Georgia, United States
HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Clinique du Quartier Latin
- Target Recruit Count
- 40
- Registration Number
- NCT04334551
- Locations
- 🇲🇶
CHU Martinique, Fort-de-France, Fort De France, Martinique
🇨🇦Clinique Du Quartier Latin, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.